Adhera Therapeutics Stock Net Income
Adhera Therapeutics fundamentals help investors to digest information that contributes to Adhera Therapeutics' financial success or failures. It also enables traders to predict the movement of Adhera Pink Sheet. The fundamental analysis module provides a way to measure Adhera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adhera Therapeutics pink sheet.
Adhera |
Adhera Therapeutics Company Net Income Analysis
Adhera Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Adhera Therapeutics Net Income | (6.35 M) |
Most of Adhera Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adhera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Adhera Therapeutics reported net income of (6.35 Million). This is 101.86% lower than that of the Biotechnology sector and 109.07% lower than that of the Health Care industry. The net income for all United States stocks is 101.11% higher than that of the company.
Adhera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adhera Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Adhera Therapeutics could also be used in its relative valuation, which is a method of valuing Adhera Therapeutics by comparing valuation metrics of similar companies.Adhera Therapeutics is currently under evaluation in net income category among its peers.
Adhera Fundamentals
| Return On Asset | -4.48 | ||||
| Current Valuation | 10.55 M | ||||
| Shares Outstanding | 3.16 M | ||||
| Shares Owned By Insiders | 21.87 % | ||||
| Number Of Shares Shorted | 2.05 K | ||||
| Price To Earning | (125.83) X | ||||
| Price To Sales | 8.23 X | ||||
| Gross Profit | (157 K) | ||||
| EBITDA | (4.92 M) | ||||
| Net Income | (6.35 M) | ||||
| Cash And Equivalents | 849 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 7.35 M | ||||
| Debt To Equity | 56.30 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (6.90) X | ||||
| Cash Flow From Operations | (665 K) | ||||
| Short Ratio | 3.24 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.14 | ||||
| Market Capitalization | 2.18 M | ||||
| Total Asset | 196 K | ||||
| Retained Earnings | (42.43 M) | ||||
| Working Capital | 16.49 M | ||||
| Current Asset | 20.36 M | ||||
| Current Liabilities | 3.88 M | ||||
| Net Asset | 196 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |